Приказ основних података о документу

dc.creatorTeixo, Ricardo
dc.creatorPires, Ana Salomé
dc.creatorPereira, Eurico
dc.creatorSerambeque, Beatriz
dc.creatorMarques, Inês Alexandra
dc.creatorLaranjo, Mafalda
dc.creatorMojsilović, Slavko
dc.creatorGramignoli, Roberto
dc.creatorPonsaerts, Peter
dc.creatorSchoeberlein, Andreina
dc.creatorBotelho, Maria Filomena
dc.date.accessioned2022-09-16T12:32:42Z
dc.date.available2022-09-16T12:32:42Z
dc.date.issued2022
dc.identifier.issn1422-0067
dc.identifier.urihttp://rimi.imi.bg.ac.rs/handle/123456789/1252
dc.description.abstractThe increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.
dc.relationThis research was funded by the FOUNDATION FOR SCIENCE AND TECHNOL-OGY (FCT), Portugal through the Strategic Projects UID/NEU/04539/2019 UIDB/04539/2020,UIDP/04539/2020
dc.relationCOMPETE-FEDER, reference number POCI-01-0145-FEDER-007440
dc.relationScholarship grants from FCT and European Social Funding to R.T. (SFRH/BD/116794/2016), I.A.M.(SFRH/BD/136973/2018), B.S. (2020.07672.BD) and E.P. (2021.05543.BD)
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceInternational Journal of Molecular Sciences
dc.subjectperinatal derivatives
dc.subjectcancer
dc.subjectpreclinical studies
dc.subjectanimal models
dc.titleApplication of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies
dc.typearticle
dc.rights.licenseBY
dc.citation.issue15
dc.citation.spage8570
dc.citation.volume23
dc.identifier.doi10.3390/ijms23158570
dc.identifier.fulltexthttp://rimi.imi.bg.ac.rs/bitstream/id/2810/Application_of_Perinatal_Derivatives_on_Oncological_Preclinical_pub_2022.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу